Clarivate (CLVT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Executive summary
The annual general meeting is scheduled for May 14, 2026, with shareholders of record as of March 16, 2026, eligible to vote on key proposals including director re-elections, executive compensation, and auditor ratification.
Shareholders can vote in person, by proxy, or electronically, and are encouraged to review proxy materials and submit voting instructions promptly.
The proxy statement includes forward-looking statements regarding strategy, risk, and governance, with cautionary notes on uncertainties and risks.
Voting matters and shareholder proposals
Shareholders will vote on re-election of ten directors, advisory approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditors for 2026.
All proposals require a simple majority of votes cast; abstentions and broker non-votes do not affect outcomes for non-routine matters.
Shareholder proposals for the 2027 meeting must be submitted by December 2, 2026, for inclusion in the proxy statement.
Board of directors and corporate governance
The board consists of ten directors, nine of whom are independent, with diverse backgrounds in finance, academia, technology, and global business.
Board committees (Audit, Human Resources and Compensation, Nominating and Governance, Finance) are fully independent and oversee key areas including risk, strategy, and sustainability.
Annual board and committee self-evaluations, director share ownership guidelines, and a code of conduct are in place.
Director nomination rights are granted to certain investors under specific agreements, and board refreshment is ongoing.
Latest events from Clarivate
- Q2 2026 revenues fell 5% to $587.3M; strong margins and LS&H divestiture drive debt reduction.CLVT
Q2 2026 - $600M LS&H divestiture sharpens focus, boosts margins, and strengthens financial outlook.CLVT
M&A announcement - Q1 2026 saw margin expansion, debt reduction, and progress on LS&H segment divestiture.CLVT
Q1 2026 - Votes will be held on director re-elections, executive pay, and auditor reappointment.CLVT
Proxy filing - Accelerating recurring revenue and AI-driven innovation while divesting Life Sciences to boost growth.CLVT
Wolfe FinTech Forum - Exceeded guidance, improved recurring revenue, and set 2026 growth targets amid portfolio shift.CLVT
Q4 2025 - Q2 revenue fell and net loss widened on impairment, but guidance and renewal rates held firm.CLVT
Q2 2024 - Guidance lowered for organic growth, but AI innovation and buybacks signal a strategic shift.CLVT
Oppenheimer 27th Virtual Annual Technology, Internet & Communications Conference - AI-driven innovation and recurring revenue focus set the stage for accelerated growth and margin gains.CLVT
Stifel 2024 Cross Sector Insight Conference